keyword
MENU ▼
Read by QxMD icon Read
search

Dronedarone

keyword
https://www.readbyqxmd.com/read/28160722/molecular-modeling-simulation-and-docking-study-of-ebola-virus-glycoprotein
#1
Nasir Ahmad, Aqsa Farman, Syed Lal Badshah, Ata Ur Rahman, Haroon Ur Rashid, Khalid Khan
Ebola virus (EBOV) is a filamentous, enveloped, non-segmented, negative-strand ribonucleic acid (RNA) virus which belongs to family Filoviridae. Ebola virus includes different glycoproteins each of which plays their roles in different aspects of viral life cycle. In this study secreted glycoprotein (Q7T9E0) of Ebola virus was acquired from Uniprot. The formation of alpha helix and beta sheets of secondary structures were predicted through online servers. Higher flexibility and disordered regions of proteins were determined through RONN, GLOBPLOT and DISSEMBLE...
December 19, 2016: Journal of Molecular Graphics & Modelling
https://www.readbyqxmd.com/read/28053220/application-of-static-modeling-in-the-prediction-of-in-vivo-drug-drug-interactions-between-rivaroxaban-and-anti-arrhythmic-agents-based-on-in-vitro-inhibition-studies
#2
Eleanor Jing Yi Cheong, Janice Jia Ni Goh, Yanjun Hong, Gopalakrishnan Venkatesan, Yuanjie Liu, Gigi Ngar Chee Chiu, Pipin Kojodjojo, Eric Chun Yong Chan
Rivaroxaban, a direct Factor Xa inhibitor, is indicated for stroke prevention in non-valvular atrial fibrillation (AF). Studies have revealed that the clearance of rivaroxaban is largely attributed to CYP3A4, CYP2J2 metabolism and P-gp efflux pathways. Amiodarone and dronedarone are anti-arrhythmic agents employed in AF management. Amiodarone, dronedarone and their major metabolites, N-desethylamiodarone (NDEA) and N-desbutyldronedarone (NDBD) demonstrate inhibitory effects on CYP3A4 and CYP2J2 with FDA recommended probe substrates...
January 4, 2017: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/28044249/evaluation-of-facebook-and-twitter-monitoring-to-detect-safety-signals-for-medical-products-an-analysis-of-recent-fda-safety-alerts
#3
Carrie E Pierce, Khaled Bouri, Carol Pamer, Scott Proestel, Harold W Rodriguez, Hoa Van Le, Clark C Freifeld, John S Brownstein, Mark Walderhaug, I Ralph Edwards, Nabarun Dasgupta
INTRODUCTION: The rapid expansion of the Internet and computing power in recent years has opened up the possibility of using social media for pharmacovigilance. While this general concept has been proposed by many, central questions remain as to whether social media can provide earlier warnings for rare and serious events than traditional signal detection from spontaneous report data. OBJECTIVE: Our objective was to examine whether specific product-adverse event pairs were reported via social media before being reported to the US FDA Adverse Event Reporting System (FAERS)...
January 2, 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/27992867/dronedarone-modulates-m1-and-m3-muscarinic-receptors-with-subtype-selectivity-functional-selectivity-and-probe-dependence
#4
Gihan M Jayasuriya, Gwendolynne Elmslie, Ethan S Burstein, John Ellis
We have previously reported that amiodarone interacts with a novel allosteric site on muscarinic receptors. Amiodarone's most striking effect is to enhance the maximal response elicited by muscarinic agonists at the M1, M3, and M5 receptors. Furthermore, the quaternary analog N-ethylamiodarone (NEA) is inhibitory at these receptors and appears to compete with amiodarone at that allosteric site. In the present studies, we show that dronedarone also modulates Gq-mediated responses at M1 and M3, although in a more discriminating manner...
December 20, 2016: Pharmacology
https://www.readbyqxmd.com/read/27863364/interactions-of-digitalis-and-class-iii-antiarrhythmic-drugs-amiodarone-versus-dronedarone
#5
Gerrit Frommeyer, Dirk Puckhaber, Christian Ellermann, Dirk G Dechering, Simon Kochhäuser, Patrick Leitz, Florian Reinke, Lars Eckardt
BACKGROUND: A post hoc analysis of the PALLAS trial suggested possible interactions of dronedarone and digitalis glycosides. The aim of the present study was to compare the effects dronedarone or amiodarone in combination with digitalis glycosides. METHODS AND RESULTS: Eleven female rabbits underwent chronic oral treatment with amiodarone (50mg/kg/d for 6weeks). Ten rabbits were treated with dronedarone (50mg/kg/d for 6weeks). Ten rabbits were used as controls. Hearts were isolated and Langendorff-perfused...
February 1, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/27760589/bioanalytical-method-validation-for-dronedarone-and-duloxetine-in-blood-serum
#6
Alka Bali, Renu Chadha, Gulshan Bansal
The present work relates to the development and validation of reversed-phase HPLC-UV-photodiode array methods for the estimation of two drugs in blood serum: dronedarone hydrochloride (DDN), a class III antiarrhythmic drug, and duloxetine hydrochloride (DLX), an antidepressant. Chromatographic analysis of DLX was carried out on a Nucleodur C18 column (250 × 4.6 mm, 5 μm) using ammonium acetate buffer (32 mM, pH 5.5) and acetonitrile (40 + 60, v/v; flow rate of 1.0 mL/min; detection wavelength of 290 nm) as the mobile phase...
October 18, 2016: Journal of AOAC International
https://www.readbyqxmd.com/read/27758968/the-novel-use-of-ranolazine-as-an-antiarrhythmic-agent-in-atrial-fibrillation
#7
REVIEW
C Michael White, Elaine Nguyen
OBJECTIVE: To review the limitations of current antiarrhythmic drugs in atrial fibrillation (AF) and discuss the rationale and clinical trials supporting the use of ranolazine in AF. DATA SOURCES: MEDLINE was searched from 1980 to September 2016 using the terms ranolazine, atrial fibrillation, coronary artery bypass grafting, and valve surgery STUDY SELECTION AND DATA EXTRACTION: English-language studies and reviews assessing antiarrhythmic drugs, including ranolazine, were incorporated...
October 6, 2016: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/27719634/outcomes-with-dronedarone-in-atrial-fibrillation-what-differences-between-real-world-practice-and-trials-a-meta-analysis-and-meta-regression-analysis
#8
Igor Diemberger, Giulia Massaro, Maria Letizia Bacchi Reggiani, Stefano Lorenzetti, Mauro Biffi, Matteo Ziacchi, Cristian Martignani, Giuseppe Boriani
Dronedarone was found to have divergent safety profiles in randomized controlled trials (RCT) in term of cardiac death and overall mortality. We decided to evaluate all available evidence on the cardiovascular safety of this drug. A systematic search was made of the MEDLINE and the Cochrane Central Register of Controlled Trials from January 2003 through April 2016 for RCT comparing dronedarone to placebo/active control, to provide the most accurate estimate of the effects of this agent and observational cohort studies (OBS) reporting clinical outcomes in patients treated with dronedarone, according to current guidelines, to obtain a real-life comparator for the findings summarized by RTC analysis...
October 6, 2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/27693025/concomitant-rivaroxaban-and-dronedarone-administration-in-patients-with-nonvalvular-atrial-fibrillation
#9
Carlos Escobar, Martín Arceluz, Rosa Montes de Oca, Ricardo Mori, José Luis López-Sendón, José Luis Merino
No abstract text is available yet for this article.
February 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/27533520/rise-and-fall-of-dronedarone-the-need-for-new-drugs
#10
EDITORIAL
Bernhard M Kaess, Joachim R Ehrlich
No abstract text is available yet for this article.
April 2016: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/27520758/interaction-between-amiodarone-and-hepatitis-c-virus-nucleotide-inhibitors-in-human-induced-pluripotent-stem-cell-derived-cardiomyocytes-and-hek-293-cav1-2-over-expressing-cells
#11
Armando Lagrutta, Haoyu Zeng, John Imredy, Bharathi Balasubramanian, Spencer Dech, Edward Lis, Jixin Wang, Jin Zhai, Joseph DeGeorge, Frederick Sannajust
Several clinical cases of severe bradyarrhythmias have been reported upon co-administration of the Hepatitis-C NS5B Nucleotide Polymerase Inhibitor (HCV-NI) direct-acting antiviral agent, sofosbuvir (SOF), and the Class-III anti-arrhythmic amiodarone (AMIO). We model the cardiac drug-drug interaction (DDI) between AMIO and SOF, and between AMIO and a closely-related SOF analog, MNI-1 (Merck Nucleotide Inhibitor #1), in functional assays of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), to provide mechanistic insights into recently reported clinical cases...
October 1, 2016: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/27517661/long-term-adherence-to-dronedarone-in-patients-with-atrial-arrhythmias
#12
Susanne Löbe, Silke John, Jelena Kornej, Gerhard Hindricks, Andreas Bollmann, Daniela Husser
No abstract text is available yet for this article.
November 1, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27479092/clinical-experience-of-prescribing-dabigatran-etexilate-with-dronedarone-the-role-of-therapeutic-drug-monitoring
#13
Janet Lock, Raj K Patel, Carl Brookes, Jignesh P Patel
No abstract text is available yet for this article.
December 2016: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/27477654/convergent-synthesis-of-dronedarone-an-antiarrhythmic-agent
#14
Takashi Okitsu, Mizuki Ogasahara, Akimori Wada
We have developed a convergent synthesis of dronedarone, an antiarrhythmic agent. The key steps of the process are the construction of a benzofuran skeleton by iodocyclization and the carbonylative Suzuki-Miyaura cross-coupling for biaryl ketone formation. This synthetic route required only eight steps from 2-amino-4-nitrophenol in 23% overall yield.
2016: Chemical & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/27461025/the-use-of-dronedarone-for-recurrent-ventricular-tachycardia-a-case-report-and-review-of-the-literature
#15
Jacques Rizkallah, Vikas Kuriachan, L Brent Mitchell
BACKGROUND: Dronedarone is a benzofuran derivative resembling amiodarone that was intended to reduce the iodine-associated tissue deposition and organ toxicity seen with the latter. The utility of dronedarone for patients with ventricular arrhythmias has not been thoroughly evaluated. We present our experience with its use to treat refractory ventricular tachycardia storm and review the literature. CASE PRESENTATION: An 85 year-old gentleman with multiple medical comorbidities including ischemic and non-ischemic cardiomyopathy with severe biventricular systolic dysfunction presented with ventricular tachycardia storm...
July 27, 2016: BMC Research Notes
https://www.readbyqxmd.com/read/27418969/the-evolving-landscape-of-oral-anti-arrhythmic-prescriptions-for-atrial-fibrillation-in-england-1998-2014
#16
Carl Hayward, Hitesh C Patel, Ketna Patel, Carlo Di Mario, Alexander R Lyon, Syed Y Ahsan, Edward Rowland
AIMS: An important decision in the management of patients with atrial fibrillation is whether to adopt a rate or rhythm control strategy. Options for the latter include oral membrane-active anti-arrhythmic drugs (AADs) or catheter ablation. Recent prescription trends may have been affected by the introduction of dronedarone and an increasing number of reports suggesting increased mortality in those taking AADs. We describe the trend in oral AAD prescriptions in England in the period 1998-2014...
April 2016: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/27261835/ranolazine-electrophysiologic-effect-efficacy-and-safety-in-patients-with-cardiac-arrhythmias
#17
REVIEW
Mohammad Shenasa, Hamid Assadi, Shahriar Heidary, Hossein Shenasa
Ranolazine is currently approved as an antianginal agent in patients with chronic angina (class IIA). Ranolazine exhibits antiarrhythmic effects that are related to its multichannel blocking effect, predominantly inhibition of late sodium (late INa) current and the rapid potassium rectifier current (IKr), as well as ICa, late ICa, and INa-Ca. It also suppresses the early and delayed after depolarizations. Ranolazine is effective in the suppression of atrial and ventricular arrhythmias (off-label use) without significant proarrhythmic effect...
2016: Cardiac Electrophysiology Clinics
https://www.readbyqxmd.com/read/27261834/dronedarone-basic-pharmacology-and-clinical-use
#18
REVIEW
Rafik Tadros, Stanley Nattel, Jason G Andrade
Dronedarone is the newest antiarrhythmic drug approved for the maintenance of sinus rhythm in patients with nonpermanent atrial fibrillation (AF). It is a multi-channel blocker with diverse electrophysiologic properties. Dronedarone decreases the incidence of AF recurrence and the ventricular rate during recurrence. Dronedarone decreases rates of cardiovascular hospitalizations in patients with paroxysmal and persistent AF. Dronedarone increases mortality in patients with permanent AF and those with moderate-severe heart failure, and should thus be avoided in these populations...
2016: Cardiac Electrophysiology Clinics
https://www.readbyqxmd.com/read/27197836/dronedarone-and-amiodarone-induce-dyslipidemia-and-thyroid-dysfunction-in-rats
#19
Li-Qin Jiang, Shan-Jiang Chen, Jian-Jiang Xu, Zhang Ran, Wang Ying, Sheng-Gang Zhao
BACKGROUND/AIMS: Amiodarone, a thyroid hormone-like molecule, can induce dyslipidemia and thyroid dysfunction. However, the effects of dronedarone on lipid metabolism and of both dronedarone and amiodarone on thyroid function and lipid metabolism remain unknown. METHODS: Fifty male Sprague-Dawley rats were randomly divided into 5 groups (10 in each group): normal control (NC), amiodarone-treated (AMT), dronedarone-treated (DRT), rats treated with amiodarone combined with polyene phosphatidylcholine (AC), and rats treated with dronedarone combined with polyene phosphatidylcholine (DC)...
2016: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/27194397/the-pharmacokinetics-of-dronedarone-in-normolipidemic-and-hyperlipidemic-rats
#20
Yousef A Bin Jardan, Dion R Brocks
The objectives of the current study were to characterize the pharmacokinetic profile of dronedarone in the rat, and to examine the effect of hyperlipidemia on its pharmacokinetics. Single doses of dronedarone were administered to rats intravenously (4 mg/kg), orally (55 mg/kg) and intraperitoneally (65 mg/kg). To induce hyperlipidemia, some of the rats were administered intraperitoneal doses of poloxamer 407 before giving an oral dose of dronedarone. After intravenous doses of 4 mg/kg dronedarone, plasma clearance and volume of distribution at steady-state were 25...
September 2016: Biopharmaceutics & Drug Disposition
keyword
keyword
15798
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"